Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | THPO | P40225 | 1/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.72 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394388 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL6573096 | 1.00 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL11429950 | 0.87 | CYP3A4 (0.76) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL11429945 | 0.87 | CYP3A4 (0.76) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL13838287 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL14291425 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL947479 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL22891821 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL3230067 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Formestane SCHEMBL25717 | 0.85 | CYP3A4 (1.00) | CYP3A4TSHRTHPOHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409512-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | Aventis Pharma S.A. (FR) | 2004-04-21 | — | — | EP | disclosed |
| US-6413951-B2 | ENZYME INHIBITOR | AVENTIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2002000681-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | AVENTIS PHARMA S.A. (FR) | 2002-01-03 | — | — | WO | disclosed |
| EP-0650495-B1 | IMPROVED ANTIANDROGENS | ENDORECHERCHE INC (CA) | 2000-11-08 | — | — | EP | disclosed |
| US-6015806-A | TOPICAL USE IN THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES ASSOCIATED WITH THE SKIN. | ENDORECHERCHE (CA) | 2000-01-18 | — | — | US | disclosed |
| EP-0650495-A1 | IMPROVED ANTIANDROGENS | ENDORECHERCHE INC. (CA) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994026767-A1 | IMPROVED ANTIANDROGENS | ENDORECHERCHE INC. (CA) | 1994-11-24 | — | — | WO | disclosed |
| US-4904650-A | Substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.P.A. (IT) | 1990-02-27 | — | — | US | disclosed |
| US-4808616-A | 6-substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | CYP17A1, HSD17B11, HSD3B1 | CYP3A4 167/4885TSHR 550/4885THPO 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.